In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

NCT05974345 · clinicaltrials.gov ↗

COMPLETED

Status

204691

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease

Interventions

DRUG: Inclisiran sodium
DRUG: Placebo
DRUG: Ezetimibe
DRUG: Evolocumab

Sponsor

Novartis Pharmaceuticals